ArticleScientific reports2025
Long-term dynamics of cytomegalovirus-specific antibodies in a longitudinal cohort of children followed up for the first decade of life.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cytomegalovirus (CMV) causes infections that last a lifetime and are primarily contracted in childhood. Congenital transmitted CMV is associated with severe neurological sequelae and can cause life-threatening disease in immunocompromised individuals. Although antibodies are generally presumed to correlate with protection, their long-term dynamics remain poorly understood. We aimed to determine the longevity of CMV-specific antibodies in a low-income setting in Kilifi County, Kenya. To track long-term antibody dynamics, we conducted longitudinal surveillance of annually collected serum samples and assayed for antibodies against the CMV tegument phosphoprotein (pp150). The duration of effective immunity against re-infection was estimated using piecewise regression modelling. Serum antibody to CMV was measured in 123 children recruited within the first five years of life and sampled annually over a median of 10 years (range: 7-14). Antibodies to the CMV pp150 showed a cyclic trend of acquisition and loss at the population level. Individually, we observed early antibody acquisition, followed by decline and rebound. Regression analysis identified a 7.57-year inflection point in antibody trajectories, marking a transition from waning to re-accumulation - potentially reflecting natural boosting events in a population where CMV infection occurs early in life. The data show a clear pattern of early natural infection, followed by repeated patterns of antibody acquisition, loss, and re-acquisition over the first decade and a half of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.